Periostin is up-regulated in high grade and high stage prostate cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Tischler, Verena ^a   Fritzsche, Florian R ^a   Wild, Peter J ^a   Stephan, Carsten ^b   Seifert, Hans Helge ^a   Riener, Marc Oliver ^a   Hermanns, Thomas ^a   Mortezavi, Ashkan ^a   Gerhardt, Josefine ^a   Schraml, Peter ^a   Jung, Klaus ^b   Moch, Holger ^a   Soltermann, Alex ^a   Kristiansen, Glen ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR RUNX2; CELL ADHESION MOLECULE; POSTN PROTEIN, HUMAN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER GRADING; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PRIMARY TUMOR; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROSTATE TUMOR; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STROMA CELL; SURVIVAL TIME; CHEMISTRY; CHI SQUARE DISTRIBUTION; EPITHELIUM CELL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; TIME; UPREGULATION;

AGED; CELL ADHESION MOLECULES; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; STROMAL CELLS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 77953212306     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-273     Document Type: Article

References (44)

1. Takeshita S, Kikuno R, Tezuka K, Amann E. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J 1993, 294(Pt 1):271-278. 1134594, 8363580.
2. Horiuchi K, Amizuka N, Takeshita S, Takamatsu H, Katsuura M, Ozawa H, Toyama Y, Bonewald LF, Kudo A. Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta. J Bone Miner Res 1999, 14(7):1239-1249. 10.1359/jbmr.1999.14.7.1239, 10404027.
3. Oshima A, Tanabe H, Yan T, Lowe GN, Glackin CA, Kudo A. A novel mechanism for the regulation of osteoblast differentiation: transcription of periostin, a member of the fasciclin I family, is regulated by the bHLH transcription factor, twist. Journal of cellular biochemistry 2002, 86(4):792-804. 10.1002/jcb.10272, 12210745.
4. Kruzynska-Frejtag A, Machnicki M, Rogers R, Markwald RR, Conway SJ. Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation. Mechanisms of development 2001, 103(1-2):183-188. 10.1016/S0925-4773(01)00356-2, 11335131.
5. Kruzynska-Frejtag A, Wang J, Maeda M, Rogers R, Krug E, Hoffman S, Markwald RR, Conway SJ. Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Dev Dyn 2004, 229(4):857-868. 10.1002/dvdy.10453, 15042709.
6. Wilde J, Yokozeki M, Terai K, Kudo A, Moriyama K. The divergent expression of periostin mRNA in the periodontal ligament during experimental tooth movement. Cell and tissue research 2003, 312(3):345-351. 10.1007/s00441-002-0664-2, 12761672.
7. Nakazawa T, Nakajima A, Seki N, Okawa A, Kato M, Moriya H, Amizuka N, Einhorn TA, Yamazaki M. Gene expression of periostin in the early stage of fracture healing detected by cDNA microarray analysis. J Orthop Res 2004, 22(3):520-525. 10.1016/j.orthres.2003.10.007, 15099630.
8. Li P, Oparil S, Feng W, Chen YF. Hypoxia-responsive growth factors upregulate periostin and osteopontin expression via distinct signaling pathways in rat pulmonary arterial smooth muscle cells. J Appl Physiol 2004, 97(4):1550-1558. discussion 1549, 10.1152/japplphysiol.01311.2003, 15121739.
9. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Gishizky ML, Marks JR, Wang XF. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Molecular and cellular biology 2004, 24(9):3992-4003. 10.1128/MCB.24.9.3992-4003.2004, 387763, 15082792.
10. Lindner V, Wang Q, Conley BA, Friesel RE, Vary CP. Vascular injury induces expression of periostin: implications for vascular cell differentiation and migration. Arterioscler Thromb Vasc Biol 2005, 25(1):77-83.
11. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, et al. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 2008, 205(2):295-303. 10.1084/jem.20071297, 2271007, 18208976.
12. Litvin J, Zhu S, Norris R, Markwald R. Periostin family of proteins: therapeutic targets for heart disease. Anat Rec A Discov Mol Cell Evol Biol 2005, 287(2):1205-1212.
13. Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004, 5(4):329-339. 10.1016/S1535-6108(04)00081-9, 15093540.
14. Yan W, Shao R. Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 2006, 281(28):19700-19708. 10.1074/jbc.M601856200, 16702213.
15. Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res 2002, 62(18):5358-5364.
16. Baril P, Gangeswaran R, Mahon PC, Caulee K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T, Lemoine NR. Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway. Oncogene 2007, 26(14):2082-2094. 10.1038/sj.onc.1210009, 17043657.
17. Erkan M, Kleeff J, Gorbachevski A, Reiser C, Mitkus T, Esposito I, Giese T, Buchler MW, Giese NA, Friess H. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology 2007, 132(4):1447-1464. 10.1053/j.gastro.2007.01.031, 17408641.
18. Fluge O, Bruland O, Akslen LA, Lillehaug JR, Varhaug JE. Gene expression in poorly differentiated papillary thyroid arcinomas. Thyroid 2006, 16(2):161-175. 10.1089/thy.2006.16.161, 16676402.
19. Forsti A, Jin Q, Altieri A, Johansson R, Wagner K, Enquist K, Grzybowska E, Pamula J, Pekala W, Hallmans G, et al. Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. Breast cancer research and treatment 2007, 101(1):83-93. 10.1007/s10549-006-9265-1, 16807673.
20. Fukushima N, Kikuchi Y, Nishiyama T, Kudo A, Fukayama M. Periostin deposition in the stroma of invasive and intraductal neoplasms of the pancreas. Mod Pathol 2008, 21(8):1044-53. 10.1038/modpathol.2008.77, 18487994.
21. Gonzalez HE, Gujrati M, Frederick M, Henderson Y, Arumugam J, Spring PW, Mitsudo K, Kim HW, Clayman GL. Identification of 9 genes differentially expressed in head and neck squamous cell carcinoma. Archives of otolaryngology--head & neck surgery 2003, 129(7):754-759. 10.1001/archotol.129.7.754, 12874078.
22. Kanno A, Satoh K, Masamune A, Hirota M, Kimura K, Umino J, Hamada S, Satoh A, Egawa S, Motoi F, et al. Periostin, secreted from stromal cells, has biphasic effect on cell migration and correlates with the epithelial to mesenchymal transition of human pancreatic cancer cells. International journal of cancer 2008, 122(12):2707-2718.
23. Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, et al. Periostin Is Expressed in Pericryptal Fibroblasts and Cancer-associated Fibroblasts in the Colon. J Histochem Cytochem 2008, 56(8):753-764. 10.1369/jhc.2008.951061, 2443605, 18443362.
24. Kudo Y, Ogawa I, Kitajima S, Kitagawa M, Kawai H, Gaffney PM, Miyauchi M, Takata T. Periostin promotes invasion and anchorage-independent growth in the metastatic process of head and neck cancer. Cancer research 2006, 66(14):6928-6935. 10.1158/0008-5472.CAN-05-4540, 16849536.
25. Li JS, Sun GW, Wei XY, Tang WH. Expression of periostin and its clinicopathological relevance in gastric cancer. World J Gastroenterol 2007, 13(39):5261-5266.
26. Puglisi F, Puppin C, Pegolo E, Andreetta C, Pascoletti G, D'Aurizio F, Pandolfi M, Fasola G, Piga A, Damante G, et al. Expression of periostin in human breast cancer. Journal of clinical pathology 2008, 61(4):494-498. 10.1136/jcp.2007.052506, 17938160.
27. Puppin C, Fabbro D, Dima M, Di Loreto C, Puxeddu E, Filetti S, Russo D, Damante G. High periostin expression correlates with aggressiveness in papillary thyroid carcinomas. The Journal of endocrinology 2008, 197(2):401-408. 10.1677/JOE-07-0618, 18434370.
28. Sasaki H, Dai M, Auclair D, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB. Serum level of the periostin, a homologue of an insect cell adhesion molecule, as a prognostic marker in nonsmall cell lung carcinomas. Cancer 2001, 92(4):843-848. 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P, 11550156.
29. Sasaki H, Lo KM, Chen LB, Auclair D, Nakashima Y, Moriyama S, Fukai I, Tam C, Loda M, Fujii Y. Expression of Periostin, homologous with an insect cell adhesion molecule, as a prognostic marker in non-small cell lung cancers. Jpn J Cancer Res 2001, 92(8):869-873.
30. Sasaki H, Sato Y, Kondo S, Fukai I, Kiriyama M, Yamakawa Y, Fuji Y. Expression of the periostin mRNA level in neuroblastoma. Journal of pediatric surgery 2002, 37(9):1293-1297. 10.1053/jpsu.2002.34985, 12194119.
31. Siriwardena BS, Kudo Y, Ogawa I, Kitagawa M, Kitajima S, Hatano H, Tilakaratne WM, Miyauchi M, Takata T. Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer. British journal of cancer 2006, 95(10):1396-1403. 10.1038/sj.bjc.6603431, 2360586, 17060937.
32. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G. Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res 2008, 14(22):7430-7437. 10.1158/1078-0432.CCR-08-0935, 19010860.
33. Riener MO, Fritzsche FR, Soll C, Pestalozzi BC, Probst-Hensch N, Clavien PA, Jochum W, Soltermann A, Moch H, Kristiansen G. Expression of the Extracellular Matrix Protein Periostin in Liver Tumors and Bile Duct Carcinomas. Histopathology 2010,
34. Soltermann A, Ossola R, Kilgus-Hawelski S, von Eckardstein A, Suter T, Aebersold R, Moch H. N-glycoprotein profiling of lung adenocarcinoma pleural effusions by shotgun proteomics. Cancer 2008, 114(2):124-133. 10.1002/cncr.23349, 18327805.
35. Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S. The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma. Prostate 2009, 69(13):1398-403. 10.1002/pros.20988, 19479898.
36. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 2008, 98(3):604-610. 10.1038/sj.bjc.6604199, 2243142, 18212746.
37. Kong D, Wang Z, Sarkar SH, Li Y, Banerjee S, Saliganan A, Kim HR, Cher ML, Sarkar FH. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26(6):1425-1435. 10.1634/stemcells.2007-1076, 18403754.
38. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW. Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213(2):374-383. 10.1002/jcp.21223, 17680632.
39. Jiang YG, Luo Y, He DL, Li X, Zhang LL, Peng T, Li MC, Lin YH. Role of Wnt/beta-catenin signaling pathway in epithelial-mesenchymal transition of human prostate cancer induced by hypoxia-inducible factor-1alpha. Int J Urol 2007, 14(11):1034-1039. 10.1111/j.1442-2042.2007.01866.x, 17956532.
40. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008, 68(7):2479-2488. 10.1158/0008-5472.CAN-07-2559, 18381457.
41. Castronovo V, Waltregny D, Kischel P, Roesli C, Elia G, Rybak JN, Neri D. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics 2006, 5(11):2083-2091. 10.1074/mcp.M600164-MCP200, 16861259.
42. Sasaki H, Dai M, Auclair D, Kaji M, Fukai I, Kiriyama M, Yamakawa Y, Fujii Y, Chen LB. Serum level of the periostin, a homologue of an insect cell adhesion molecule, in thymoma patients. Cancer letters 2001, 172(1):37-42. 10.1016/S0304-3835(01)00633-4, 11595127.
43. Fritzsche FR, Jung M, Tolle A, Wild P, Hartmann A, Wassermann K, Rabien A, Lein M, Dietel M, Pilarsky C, et al. ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol 2008, 54(5):1097-1106. 10.1016/j.eururo.2007.11.034, 18061337.
44. Kudo Y, Siriwardena BS, Hatano H, Ogawa I, Takata T. Periostin: novel diagnostic and therapeutic target for cancer. Histol Histopathol 2007, 22(10):1167-1174.